Novartis India Ltd
- Market Cap ₹ 2,053 Cr.
- Current Price ₹ 831
- High / Low ₹ 1,111 / 745
- Stock P/E 19.3
- Book Value ₹ 314
- Dividend Yield 3.01 %
- ROCE 17.0 %
- ROE 13.2 %
- Face Value ₹ 5.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Stock is providing a good dividend yield of 3.01%.
- Company has delivered good profit growth of 58.5% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 82.3%
Cons
- The company has delivered a poor sales growth of -4.06% over past five years.
- Company has a low return on equity of 12.7% over last 3 years.
- Earnings include an other income of Rs.41.2 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 859 | 870 | 690 | 656 | 564 | 491 | 438 | 381 | 400 | 379 | 335 | 356 | 355 | |
| 861 | 874 | 656 | 631 | 570 | 478 | 426 | 355 | 373 | 314 | 270 | 265 | 254 | |
| Operating Profit | -1 | -4 | 34 | 25 | -6 | 12 | 12 | 27 | 27 | 65 | 65 | 91 | 101 |
| OPM % | -0% | -0% | 5% | 4% | -1% | 2% | 3% | 7% | 7% | 17% | 19% | 26% | 28% |
| 95 | 101 | 207 | 71 | 172 | 78 | 36 | 33 | -17 | 58 | 62 | 42 | 41 | |
| Interest | 0 | 0 | 0 | 1 | 6 | 2 | 6 | 8 | 5 | 2 | 1 | 1 | 1 |
| Depreciation | 4 | 4 | 3 | 4 | 3 | 3 | 13 | 12 | 10 | 6 | 3 | 2 | 2 |
| Profit before tax | 90 | 93 | 237 | 92 | 158 | 86 | 29 | 40 | -4 | 115 | 123 | 130 | 139 |
| Tax % | -10% | 15% | 16% | 38% | 50% | 40% | 65% | 48% | -3% | 10% | 31% | 23% | |
| 99 | 79 | 198 | 57 | 78 | 52 | 10 | 21 | -4 | 103 | 85 | 101 | 107 | |
| EPS in Rs | 30.83 | 24.75 | 62.04 | 20.33 | 31.74 | 20.97 | 4.08 | 8.46 | -1.51 | 41.86 | 34.50 | 40.87 | 43.18 |
| Dividend Payout % | 32% | 40% | 16% | 49% | 32% | 48% | 245% | 118% | -663% | 113% | 72% | 61% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -9% |
| 5 Years: | -4% |
| 3 Years: | -4% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 58% |
| 3 Years: | 35% |
| TTM: | 22% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 6% |
| 3 Years: | 6% |
| 1 Year: | -23% |
| Return on Equity | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 9% |
| 3 Years: | 13% |
| Last Year: | 13% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 16 | 14 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 |
| Reserves | 945 | 986 | 1,178 | 906 | 721 | 747 | 708 | 699 | 679 | 763 | 732 | 773 | 763 |
| 0 | -0 | -0 | -0 | -0 | -0 | 68 | 62 | 24 | 22 | 7 | 5 | 4 | |
| 241 | 244 | 239 | 230 | 377 | 223 | 289 | 229 | 242 | 186 | 173 | 158 | 153 | |
| Total Liabilities | 1,202 | 1,246 | 1,433 | 1,150 | 1,111 | 982 | 1,078 | 1,002 | 958 | 983 | 925 | 948 | 932 |
| 8 | 8 | 6 | 6 | 5 | 15 | 76 | 64 | 24 | 19 | 7 | 5 | 4 | |
| CWIP | -0 | -0 | 0 | 0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Investments | 0 | 0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| 1,194 | 1,238 | 1,426 | 1,144 | 1,106 | 967 | 1,001 | 938 | 934 | 964 | 918 | 943 | 928 | |
| Total Assets | 1,202 | 1,246 | 1,433 | 1,150 | 1,111 | 982 | 1,078 | 1,002 | 958 | 983 | 925 | 948 | 932 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5 | -60 | 57 | -41 | 161 | -194 | -23 | -69 | 39 | 45 | 113 | 75 | |
| 22 | 719 | -630 | 424 | 69 | 274 | 56 | 95 | 87 | -153 | 33 | -3 | |
| -38 | -38 | -39 | -332 | -268 | -30 | -41 | -37 | -36 | -30 | -121 | -64 | |
| Net Cash Flow | -20 | 622 | -612 | 51 | -38 | 50 | -9 | -11 | 90 | -139 | 26 | 7 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 33 | 35 | 27 | 23 | 28 | 34 | 31 | 37 | 41 | 35 | 45 | 41 |
| Inventory Days | 96 | 103 | 92 | 104 | 84 | 111 | 117 | 119 | 117 | 99 | 82 | 74 |
| Days Payable | 100 | 98 | 89 | 87 | 158 | 168 | 145 | 137 | 148 | 108 | 112 | 93 |
| Cash Conversion Cycle | 29 | 40 | 30 | 40 | -45 | -23 | 3 | 19 | 10 | 26 | 15 | 22 |
| Working Capital Days | 353 | 6 | -35 | -14 | -99 | 7 | -1 | 62 | -23 | -37 | -59 | -45 |
| ROCE % | 10% | 9% | 22% | 9% | 17% | 12% | 5% | 6% | 6% | 15% | 16% | 17% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
29 Oct - Of newspaper advertisement regarding the publication of unaudited financial results for the quarter and half-year ended September 30, 2025.
-
Integrated Unaudited Financial Results And Limited Review Report For The Quarter And Half-Year Ended September 30, 2025.
28 Oct - Submitted unaudited financials and limited review for quarter and half-year ended September 30, 2025.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On Tuesday, October 28, 2025
28 Oct - Board approved unaudited financial results and limited review for quarter/half-year ended Sep 30, 2025.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
13 Oct - RTA certificate confirming dematerialisation compliance for quarter and half-year ended Sep 30, 2025.
-
Board Meeting Intimation for Inter Alia Considering The Unaudited Financial Results For The Half Year And Quarter Ended September 30, 2025.
30 Sep - Board meeting Oct 28 to approve Q2/H1 Sep 30, 2025 results; trading window closed Oct 1, reopens 48 hours after.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business
The company is primarily engaged in the pharmaceutical business in the area of pain management, organ transplantation, neuroscience, etc. [1]